This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Recursion
recursionpharma.bsky.social
did:plc:rvevxwxxlmkcpoouljlqlo6j
An article in BioPharmaTrend highlighted our recent earnings report, including “progress on internal assets REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor), alongside a $7 million milestone payment from Sanofi for a partnered immunology program.” https://www.biopharmatrend.com/news/recursion-reports-q2-2025-with-7m-sanofi-milestone-announces-clinical-updates-1329/
2025-08-19T14:31:22.005Z